Preoperative administration of intramuscular dezocine reduces postoperative pain for laparoscopic cholecystectomy

Zhu, Yaomin; Jing, Gui-xia; Yuan, Wei

doi:10.1016/s1674-8301(11)60047-x

Cited by 19 publications

(19 citation statements)

References 31 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were not allowed to take deep breath or cough with poor control of postoperation pain and this may lead to atelectasis and retention of secretion [4]. Previous studies have demonstrated that satisfactory postoperative pain relief can enhance patients’ recovery after surgery with better surgical outcomes, less complications and shorter length of hospital stay [5]. So effective management of acute pain after thoracotomy was necessary.…”

Section: Introductionmentioning

confidence: 99%

Effects of patient-controlled analgesia with hydromorphone or sufentanil on postoperative pulmonary complications in patients undergoing thoracic surgery: a quasi-experimental study

et al. 2018

View full text Add to dashboard Cite

ObjectiveTo compare the analgesic effects of patient-controlled intravenous analgesia (PCA) with hydromorphone and sufentanil after thoracic surgery on postoperative pulmonary complications (PPCs).MethodsA total of 142 patients who were scheduled for thoracic surgery were randomly allocated to receive PCA with hydromorphone (group A: experimental group): hydromorphone 0.2 mg/kg + dezocine 0.5 mg/kg + ramosetron 0.6 mg diluted with normal saline to 200 mL; or with sufentanil (group B: control group): sufentanil 3.0μg/kg + dezocine 0.5 mg/kg + ramosetron 0.6 mg diluted with normal saline to 200 mL. The parameters of intravenous analgesia pump were set as background dose 4 ml/h, PCA dose 1 mL, locking time 15 min. Pain NRS (numerical rating scale), Ramsay sedation score, nausea or vomiting score were evaluated at 0 h, 6 h, 12 h, 24 h, 48 h after operation. The cases of PPCs (atelectasis, pulmonary infection, respiratory failure), CRP (C-reaction protein) and inflammatory cells (white cell count and percentage of neutrophils) and blood gas analysis at 12 h after operation, length of ICU and postoperative stay were recorded for each patient.ResultsData of 136 patients were analyzed. Compared with group B (4[IQR:2,2]), the pain NRS in group A (2[IQR:4,4]) was significantly lower at 6 h after operation (P = 0.000). The CRP in group A (69.79 ± 32.13 mg/L) were lower than group B (76.76 ± 43.42 mg/L) after operation, but the difference was not significant (P = 0.427). No difference of nausea or vomiting was found between group A (7.3%) and group B (5.8%) postoperatively (P = 0.999). The PPCs were happened in 11 patients in group A (16.2%) and 22 patients in group B (32.4%) and the difference between two groups was significant (P = 0.027). Seven patients in group A (10.3%) and eighteen patients in group B (26.5%) had clinical evidence of pneumonia and the difference between two groups was significant (P = 0.014). The length of ICU and postoperative stay in group A were 2.73 h and 1.82 days less than group B respectively but the differences were not significant (P = 0.234, P = 0.186 respectively).ConclusionCompared with sufentanil, hydromorphone may provide better postoperative analgesic effect with less pulmonary complications for patients undergoing thoracic surgery, and it may accelerate patients’ rehabilitation.Trial registrationRandomized Controlled Trials ChiCTR1800014282c. Registered 3 January 2018.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of patient-controlled analgesia with hydromorphone or sufentanil on postoperative pulmonary complications in patients undergoing thoracic surgery: a quasi-experimental study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, their analgesic effects are offset by undesired adverse effects, including respiratory depression, drug addiction, and nausea and vomiting [ 3 , 5 ]. Dezocine, a mixed agonist/antagonist of opioid receptors, has been used for postoperative pain control [ 6 – 9 ]. Because of its partial μ-agonism, some common adverse effects of opioids are significantly reduced with this drug [ 10 ], indicating that it may be a good alternative for controlling postoperative pain.…”

Section: Introductionmentioning

confidence: 99%

Dezocine for Preventing Postoperative Pain: A Meta-Analysis of Randomized Controlled Trials

et al. 2015

View full text Add to dashboard Cite

BackgroundDezocine is considered to be an alternative medication for managing postoperative pain. The aim of this study was to assess the efficacy and safety of this drug in this regard.MethodsMedline, EMBASE and the Cochrane Central Register of Control Trials (CENTRAL) were searched to identify all randomized controlled trials (RCTs) that compare dezocine with placebo or dezocine with morphine on postoperative pain. The data were extracted and pooled using Mantel-Haenszel random effects model. Heterogeneity was tested using the I 2 statistic with values >50% and Chi2 test with P ≤ 0.05 indicating obvious heterogeneity between the studies.ResultsSeven trials evaluating 665 patients were included. The number of patients with at least 50% pain relief was increased (N = 234; RR 3.04, 95% CI 2.27 to 4.08) and physician (N = 465; RR 2.84, 95% CI 1.66 to 4.84) and patient satisfaction (N = 390; RR 2.81, 95% CI 1.85 to 4.26) were improved following the administration of dezocine compared with the placebo. The effects of dezocine were similar to those of morphine in terms of the number of patients reporting at least 50% pain relief within 2–6 h after surgery (N = 235; RR 1.29, 95% CI 1.15 to 1.46) and physician (N = 234; RR 1.18, 95% CI 0.93 to 1.49) and patient (N = 158; RR 1.33, 95% CI 0.93 to 1.92) satisfaction. While, the number of patients with at least 50% pain relief within 0–1 h after surgery increased following dezocine compared with morphine treatment (N = 79; RR 1.45, 95% CI 1.18 to 1.77). There was no difference in the incidence of postoperative nausea and vomiting (PONV) following dezocine treatment compared with the placebo (N = 391; RR 1.06, 95% CI 0.42 to 2.68) or morphine treatment (N = 235; RR 0.65, 95% CI 0.14 to 2.93).ConclusionDezocine is a promising analgesic for preventing postoperative pain, but further studies are required to evaluate its safety.

show abstract

“…Once known as a mu opioid receptor antagonist and kappa opioid receptor agonist, dezocine has recently been recognized as a weak mu opioid receptor agonist and kappa opioid receptor antagonist, with an inhibitory effect on the re-uptake of noradrenalin and serotonin [ 10 , 11 , 17 , 18 ]. Several reports have suggested that dezocine possesses a potent analgesic effect, and thus, it has been used in perioperative pain management [ 19 , 20 ]. It has been demonstrated that dezocine's analgesic effect at a dose of 10 mg is the same as that of either 50 mg of meperidine or 10 mg of morphine [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Additive analgesic effect of dexmedetomidine and dezocine administered intrathecally in a mouse pain model

et al. 2018

View full text Add to dashboard Cite

BackgroundIt is known that dexmedetomidine can reduce opioid requirements and that there is a synergistic effect when dexmedetomidine and morphine (a full mu opioid receptor agonist) are administered together. However, it was unclear whether a synergistic or additive effect would be observed when dexmedetomidine was co-administered with a partial mu opioid receptor agonist. The present study was designed to elucidate such effects by intrathecally co-administering dexmedetomidine and dezocine, a partial mu receptor agonist, in a mouse pain model.MethodsC57 mice (N = 165) were randomly divided into 19 groups. The tail flick test was adopted to measure the antinociceptive effects of the tested agents. The mice were divided into saline and drug groups to investigate the dose-dependent analgesic effects. Each drug was administered at fixed doses alone and in combination with one of three doses of a second drug.ResultsDezocine (0.3125 - 1.25 μg) and dexmedetomidine (0.04 - 1 μg) both enhanced the tail withdrawal latency in dose-dependent fashions. Dexmedetomidine (0.04 - 1 μg) enhanced the analgesic effect of dezocine. Dezocine (0.3125 - 1.25 μg) enhanced the analgesic effect of dexmedetomidine. Compared with the individual drug effects, the combined effects of dezocine (0.625 μg) and dexmedetomidine (0.04 μg) were more potent 15 - 60 min after injection, but they remained similar to the sum of the effects of the two individual drugs.ConclusionsDexmedetomidine and dezocine produce an additive analgesic effect on acute nociception when administered simultaneously.

show abstract

Preoperative administration of intramuscular dezocine reduces postoperative pain for laparoscopic cholecystectomy

Cited by 19 publications

References 31 publications

Effects of patient-controlled analgesia with hydromorphone or sufentanil on postoperative pulmonary complications in patients undergoing thoracic surgery: a quasi-experimental study

Effects of patient-controlled analgesia with hydromorphone or sufentanil on postoperative pulmonary complications in patients undergoing thoracic surgery: a quasi-experimental study

Dezocine for Preventing Postoperative Pain: A Meta-Analysis of Randomized Controlled Trials

Additive analgesic effect of dexmedetomidine and dezocine administered intrathecally in a mouse pain model

Contact Info

Product

Resources

About